within

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

November 18, 2024 11:15 ET | Source: BridgeBio Pharma, Inc. - Acoramidis demonstrated the earliest known time to separation in…

3 days ago

Data Storage Corporation Provides Letter to Shareholders Highlighting Recent Achievements within CloudFirst Technologies Subsidiary

CloudFirst Continues Strong Financial Performance Along with Expansion into the United Kingdom and Operational Success Following Flagship Solutions Group Integration…

2 weeks ago